Lucius Edition Enasidenib Drug Information Introduction
Enasidenib is a targeted drug specifically targeting IDH2 mutations in acute myeloid leukemia (AML). As an innovative differentiation therapy drug, it was first developed by overseas pharmaceutical companies and approved for marketing in many European and American countries for adult patients with relapsed or refractory AML. Original drugs are usually relatively expensive due to factors such as high research and development costs, patent protection, and market positioning. This has also prompted some pharmaceutical companies to develop generic versions. Among them, the "Lucius version of ensidipine" produced by Lucius Pharmaceutical Factory in Laos has gradually attracted attention.
Lucius version of Ensidipine is consistent with the original drug in terms of drug ingredients, and the core active ingredient is also Enasidenib. Enasidenib mainly restores the normal differentiation function of bone marrow cells by inhibiting the abnormal metabolic pathway of IDH2 mutant enzyme. The differences are mainly reflected in production specifications, dosage form packaging and price ranges. Common specifications include 50mg/30 tablets and 100mg/30 tablets, which can meet the needs of patients with different dosage needs. Due to differences in production locations and sales systems, the price of the Lucius version is usually lower than that of the original drug. Depending on market conditions and exchange rate fluctuations, each box may cost more than 1,000 yuan, making the overall financial burden on patients more controllable.
In terms of efficacy, current clinical experience shows that the efficacy of the Lucius version is not significantly different from that of the original drug. Its generic drug production follows internationally accepted generic drug standards, which means it needs to meet relevant requirements in terms of quality, safety and bioequivalence. Although slightly inferior to the original drug in terms of brand awareness and accumulated clinical data, for AML patients who require long-term medication, the emergence of generic drugs has broadened treatment options and made targeted therapy affordable for more patients.
It should be noted that ensidipine, whether it is the original drug or a generic drug, may cause certain side effects, such as increased bilirubin, abnormal white blood cell levels, digestive system discomfort, etc.
Reference materials:https://www.idhifa.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)